The choice of an intravenous solution for the attenuation of ischaemia/reperfusion (I/R) lung injury is still a difficult one. Although 10% (w/v) pentastarch has been used in ICU settings, its use in I/R lung injury has not been well explored. We hypothesized that this synthetic colloid substance, which maintains colloid osmotic pressure and potentially ‘seals’ capillary leaks, in combination with an anti-inflammatory agent (i.e. dexamethasone), would ameliorate I/R lung injury. After 60 min of lung ischaemia in an isolated rat lung model, lungs were reperfused for 60 min in a closed circulating system with one of the following solutions: (1) NS (0.9% normal saline), (2) NS+Dex (dexamethasone), (3) NS+Penta (pentastarch), or (4) NS+Penta+Dex. Haemodynamic changes, lung weight gain (LWG), capillary filtration coefficient (Kfc) and lung pathology were analysed. Results showed significantly lower values of Kfc and LWG in pentastarch- or dexamethasone-perfused groups as compared with those in the NS group. Dexamethasone as an additive to NS+Penta further decreased Kfc and LWG. Histopathological studies showed similar decreases in injury profiles. We conclude that reperfusion with dexamethasone and pentastarch can attenuate I/R lung injury, and that dexamethasone and pentastarch have additive effects. Our data thus suggest that the combination of a colloid substance with ‘sealing effects’ and an anti-inflammatory agent may provide a better reperfusion solution for patients with I/R lung injury or for lungs stored for transplant.
Skip Nav Destination
Article navigation
Research Article|
October 27 2000
Dexamethasone and pentastarch produce additive attenuation of ischaemia/reperfusion lung injury Available to Purchase
Chi-Huei CHIANG;
*Pulmonary Division, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
Correspondence: Dr Chi-Huei Chiang, Pulmonary Division, Tri-Service General Hospital. No. 8. Section 3, Ting-Chow Road, Taipei, Taiwan, ROC (e-mail [email protected]).
Search for other works by this author on:
Chin-Pyng WU;
Chin-Pyng WU
*Pulmonary Division, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
Search for other works by this author on:
Wann-Cherng PERNG;
Wann-Cherng PERNG
*Pulmonary Division, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
Search for other works by this author on:
Horng-Chin YAN;
Horng-Chin YAN
*Pulmonary Division, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
Search for other works by this author on:
Cheng-Ping YU
Cheng-Ping YU
†Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
March 21 2000
Revision Received:
May 22 2000
Accepted:
July 06 2000
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society and the Medical Research Society © 2000
2000
Clin Sci (Lond) (2000) 99 (5): 413–419.
Article history
Received:
March 21 2000
Revision Received:
May 22 2000
Accepted:
July 06 2000
Citation
Chi-Huei CHIANG, Chin-Pyng WU, Wann-Cherng PERNG, Horng-Chin YAN, Cheng-Ping YU; Dexamethasone and pentastarch produce additive attenuation of ischaemia/reperfusion lung injury. Clin Sci (Lond) 1 November 2000; 99 (5): 413–419. doi: https://doi.org/10.1042/cs0990413
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |